Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.

Clin Pharmacol Ther · 2023 · PMC10092050 · PMID 36164935

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The concentration‐QT analysis showed a trend of slight increase in QTcF change with increasing concentrations of T‐DXd and DXd ( Figures 2 a,b ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.